

Product Name	: Delanzomib
Synonyms	: CEP-18770; CEP18770; CEP 18770
Cat No.	: M16150
CAS Number	: 847499-27-8
Molecular Formula	: C ₂₁ H ₂₈ BN ₃ O ₅
Formula Weight	: 413.28
Chemical Name	: Boronic acid, B-[(1R)-1-[[[(2S,3R)-3-hydroxy-1-oxo-2-[[[(6-phenyl-2-pyridinyl)carbonyl]amino]butyl]amino]-3-methylbutyl]-
Description	: A potent, orally active proteasome inhibitor with IC ₅₀ of 3.8 nM against chymotrypsin-like proteasome activity; demonstrates marginal inhibition of the tryptic and peptidyl glutamyl activities of the proteasome; down-modulates the NF-kappaB activity and the expression of several NF-kappaB downstream effectors, induces apoptotic cell death in MM cells; demonstrates tumor regression in MM xenografts with favorable tumor selectivity profile. Blood Cancer Phase 1 Discontinued
Pathway	: Proteasome/Ubiquitin
Target	: Proteasome
Receptor	: Chymotrypsin-like proteasome
Solubility	: 10 mM in DMSO
SMILES	: <chem>CC(C)C[C@@H](B(O)O)NC([C@@H](NC1=NC(C2=CC=CC=C2)=CC=C1)=O)[C@H](O)C=O</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Piva R, et al. Blood. 2008 Mar 1; 111(5):2765-75. | 2. Sanchez E, et al. Br J Haematol. 2010 Feb; 148(4):569-81. | 3. Seavey MM, et al. Int Immunopharmacol. 2012 Jan; 12(1):257-70. | 4. Berkers CR, et al. Mol Pharm. 2012 May 7; 9(5):1126-35.